| Symbol | BBIO |
|---|---|
| Name | BRIDGEBIO PHARMA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 421 KIPLING STREET, PALO ALTO, California, 94301, United States |
| Telephone | +1 650 391-9740 |
| Fax | — |
| — | |
| Website | https://www.bridgebio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology. Additional info from NASDAQ: |
New Form ARS - BridgeBio Pharma, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001140361-26-016725 <b>Size:</b> 2 MB
Read moreNew Form DEFA14A - BridgeBio Pharma, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001140361-26-016724 <b>Size:</b> 3 MB
Read moreNew Form DEF 14A - BridgeBio Pharma, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001140361-26-016723 <b>Size:</b> 8 MB
Read moreBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Read moreNew Form SCHEDULE 13G/A - BridgeBio Pharma, Inc. <b>Filed:</b> 2026-04-16 <b>AccNo:</b> 0001470831-26-000373 <b>Size:</b> 8 KB
Read moreDirector Kumar Neil 🔴 sold 80.0K shares of BridgeBio Pharma, Inc. (BBIO) at $75.55 ($6.0M) Transaction Date: Apr 09, 2026 | Filing ID: 000361
Read more📋 KUMAR HALDEA REVOCABLE TRUST U/A DTD 12/19/2018 (Director) plans to sell 120K shares of BRIDGEBIO PHARMA INC (at $74.14 each, total $8.9M) Filed: Apr 09, 2026 | ID: 003358
Read moreNew Form SCHEDULE 13D/A - BridgeBio Pharma, Inc. <b>Filed:</b> 2026-04-02 <b>AccNo:</b> 0000905148-26-001499 <b>Size:</b> 38 KB
Read more(90% Positive) BRIDGEBIO PHARMA, INC. (BBIO) Provides Update on individuals living for genetic conditions
Read moreAcoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06917079 | BBO-11818 in Adult Subjects With KRAS Mutant Cancer | Phase1 | Non-Small Cell Lung Cancer | Recruiting | 2025-03-31 | 2029-09-01 | ClinicalTrials.gov |
| NCT05735015 | PTH-independent Effects of Encaleret | Phase2 | Post-Surgical Hypoparathyroidism | Completed | 2023-09-01 | 2025-08-12 | ClinicalTrials.gov |
| NCT05480865 | SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced … | Phase1 | Solid Tumor, Adult | Terminated | 2022-07-06 | 2024-08-22 | ClinicalTrials.gov |
| NCT04528836 | First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced So… | Phase1 | Tumor, Solid | Terminated | 2020-11-12 | 2024-07-30 | ClinicalTrials.gov |
| NCT04265651 | Study of Infigratinib in Children With Achondroplasia | Phase2 | Achondroplasia | Completed | 2020-03-10 | 2024-10-21 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Encaleret | Other | Phase PHASE2 | Autosomal Dominant Hypocalcemia Type 1 (ADH1) | RECRUITING | NCT07080385 |
| Encaleret | Other | Phase PHASE2 | Autosomal Dominant Hypocalcemia Type 1 (ADH1) | RECRUITING | NCT07080385 |
| Encaleret | Other | Phase PHASE2 | Autosomal Dominant Hypocalcemia Type 1 (ADH1) | RECRUITING | NCT07080385 |
| Encaleret | Other | Phase PHASE2 | Autosomal Dominant Hypocalcemia Type 1 (ADH1) | RECRUITING | NCT07080385 |
| Encaleret | Other | Phase PHASE2 | Autosomal Dominant Hypocalcemia Type 1 (ADH1) | RECRUITING | NCT07080385 |
| Encaleret | Other | Phase PHASE2 | Autosomal Dominant Hypocalcemia Type 1 (ADH1) | RECRUITING | NCT07080385 |
| Encaleret | Other | Phase PHASE2 | Autosomal Dominant Hypocalcemia Type 1 (ADH1) | RECRUITING | NCT07080385 |
| Encaleret | Other | Phase PHASE2 | Autosomal Dominant Hypocalcemia Type 1 (ADH1) | RECRUITING | NCT07080385 |
| infigratinib 0.25 mg/kg/day | DRUG | Phase PHASE2 | Hypochondroplasia | ENROLLING_BY_INVITATION | NCT06873035 |
| infigratinib 0.128 mg/kg/day | DRUG | Phase PHASE2 | Hypochondroplasia | ENROLLING_BY_INVITATION | NCT06873035 |
| Cardiac amyloidosis deep learning model | DEVICE | Approved | Cardiac Amyloidosis | COMPLETED | NCT06469372 |
| PTR-01 | DRUG | Phase PHASE2 | Recessive Dystrophic Epidermolysis Bullosa | COMPLETED | NCT05143190 |
| Iopamidol | DRUG | Phase PHASE1 | Breast Cancer | TERMINATED | NCT04504331 |
| Omnipaque 350 | DRUG | Phase PHASE1 | Breast Cancer | TERMINATED | NCT04504331 |
| Tamoxifen | DRUG | Phase PHASE1 | Breast Cancer | TERMINATED | NCT04504331 |
| BGJ398 (infigratinib) | DRUG | Phase PHASE2 | Advanced Cholangiocarcinoma | TERMINATED | NCT02150967 |
| BBP-671 | DRUG | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT04836494 |
| Placebo | DRUG | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT04836494 |
| Cisplatin | DRUG | Phase PHASE3 | Advanced Cholangiocarcinoma | TERMINATED | NCT03773302 |
| BGJ398 | DRUG | Phase PHASE3 | Advanced Cholangiocarcinoma | TERMINATED | NCT03773302 |
| sotorasib | DRUG | Phase PHASE1 | Solid Tumor, Adult | TERMINATED | NCT05480865 |
| BBP-398 | DRUG | Phase PHASE1 | Solid Tumor, Adult | TERMINATED | NCT05480865 |
| BBP-398 (Formerly known as IACS-15509) | DRUG | Phase PHASE1 | Tumor, Solid | TERMINATED | NCT04528836 |
| Placebo Comparator 0.25 mg/kg/day | DRUG | Phase PHASE3 | Achondroplasia | ACTIVE_NOT_RECRUITING | NCT06164951 |
| Infigratinib 0.25 mg/kg/day | DRUG | Phase PHASE3 | Achondroplasia | ACTIVE_NOT_RECRUITING | NCT06164951 |
| Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration | DRUG | Phase PHASE2 | Achondroplasia | NOT_YET_RECRUITING | NCT07169279 |
| Infigratinib is provided as sprinkle capsules for daily oral administration | DRUG | Phase PHASE2 | Achondroplasia | NOT_YET_RECRUITING | NCT07169279 |
| Infigratinib is provided as a single dose of minitablets for oral administration | DRUG | Phase PHASE2 | Achondroplasia | NOT_YET_RECRUITING | NCT07169279 |
| Infigratinib 0.25 mg/kg | DRUG | Phase PHASE2 | Achondroplasia | COMPLETED | NCT04265651 |
| Infigratinib 0.128 mg/kg | DRUG | Phase PHASE2 | Achondroplasia | COMPLETED | NCT04265651 |
| Infigratinib 0.064 mg/kg | DRUG | Phase PHASE2 | Achondroplasia | COMPLETED | NCT04265651 |
| Infigratinib 0.032 mg/kg | DRUG | Phase PHASE2 | Achondroplasia | COMPLETED | NCT04265651 |
| Infigratinib 0.016 mg/kg | DRUG | Phase PHASE2 | Achondroplasia | COMPLETED | NCT04265651 |
| Infigratinib | DRUG | Phase PHASE1 | Bladder Transitional Cell Carcinoma | WITHDRAWN | NCT04972253 |
| ALXN2060 | DRUG | Phase PHASE3 | Symptomatic Transthyretin Amyloid Cardiomyopathy | COMPLETED | NCT04622046 |
| Encaleret | DRUG | Phase PHASE2 | Autosomal Dominant Hypocalcemia (ADH) | COMPLETED | NCT04581629 |
| encaleret | DRUG | Phase PHASE2 | Post-Surgical Hypoparathyroidism | COMPLETED | NCT05735015 |
| Nab-paclitaxel | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| Gemcitabine | DRUG | Phase PHASE3 | Advanced Cholangiocarcinoma | TERMINATED | NCT03773302 |
| NALIRIFOX | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| Cetuximab | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| Pemetrexed | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| Platinum chemotherapy (cisplatin or carboplatin) | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| BBO-11818 | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| Pembrolizumab | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| BBO-8520 | DRUG | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |
| Bevacizumab | DRUG | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| FOLFOX | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | RECRUITING | NCT06917079 |
| Ribociclib | DRUG | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| Fulvestrant | DRUG | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| Trastuzumab | DRUG | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06625775 |
| BBO-10203 | DRUG | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT06343402 |